Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?

Group 1 - Ultragenyx Pharmaceutical Inc. is recognized as one of the best biotech stocks to buy, with a Consensus Strong Buy rating from 13 Wall Street analysts, including 12 Buys and 1 Hold [1] - The average price target for Ultragenyx is $76.83, indicating a potential upside of 111.65% from the current price of $36.30 [2] - Cantor Fitzgerald reaffirmed its Overweight rating and set a price target of $105 following the company's Q3 2025 results and financial actions [2] Group 2 - Ultragenyx reported Q3 revenue of $160 million, which was below the consensus estimate of $167 million, and an EPS of -1.81 compared to the expected -1.23 [3] - Despite the revenue shortfall, Ultragenyx maintained its full-year revenue guidance of $640 to $670 million [3] - The company sold 25% of its North American Crysvita economics for $400 million upfront, which is expected to strengthen its liquidity [3] Group 3 - Ultragenyx focuses on developing treatments for severe, debilitating, rare, and ultra-rare genetic diseases, utilizing modalities such as biologics, gene therapies, and ASOs [4]